Promising drug cocktail targets Hard-to-Treat lung cancer
NCT ID NCT07630077
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase II trial tests a combination of two drugs, trastuzumab rezetecan and ivonescimab, in 30 people with advanced non-small cell lung cancer that has HER2 gene abnormalities. The goal is to see if the combo can control the cancer and delay progression. Participants must have good performance status and either be starting first-line treatment or have failed prior therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab rezetecan and ivonescimab
What this could lead to
If successful, this could offer a new treatment option for people with advanced lung cancer that has HER2 abnormalities, potentially slowing disease progression.
What could go wrong
This is an early Phase II trial with only 30 participants, so results may not apply to everyone. The combination may cause side effects or not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Medical Oncology,Cancer Center of Sun Yat-Sen University
Guangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••